Cutting-Edge Cancer Immunotherapy
Immuno-oncology has changed the paradigm of cancer treatments
It has recently become apparent that a patient’s immune system, especially T cells, can spontaneously attack and destroy cancer cells. Nevertheless, the anti-tumoral immune system must be sustained to efficiently control cancer. Tumors express « immune checkpoints proteins » which inhibit T cell activity.
By restoring T cells immune response, Immune Checkpoint Inhibitors treatments were the first immunotherapies to revolutionize cancer treatment.
Why do immune checkpoint inhibitors fail to be efficient in some patients?
The fact that checkpoint inhibitors act via the reactivation of T cells in the tumor site leads to the failure of this treatment in most patients in which T cells are not present at the tumor site (cold tumors).
TOLLYS TL-532 is the best in class TLR3 agonist designed to induce patient T cell immune response against cancer
TL-532 induces tumor specific antigen release, activation of the immune system and a switch of the tumoral microenvironment. This leads to an intense activation of tumor-specific T cells which infiltrate the tumor bed and convert “cold tumors” into “hot tumors”. This phenomenon called “in situ vaccination” allows to eradicate cancer cells and prevent from recurrences.
TL-532 can act in standalone or be combined with Immune Checkpoint Inhibitors.
Tollys
Cutting-Edge Cancer Immunotherapy
Office
60F avenue Rockefeller
69008 Lyon, FRANCE